King's College London

Research portal

Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up

Research output: Contribution to journalArticle

Standard

Crescendo response to rituximab in oral pemphigus vulgaris : a case with 7-year follow-up. / Greenblatt, D T; Benton, E C; Groves, R W; Setterfield, J F.

In: Clinical and Experimental Dermatology, Vol. 41, No. 5, 07.2016, p. 529-32.

Research output: Contribution to journalArticle

Harvard

Greenblatt, DT, Benton, EC, Groves, RW & Setterfield, JF 2016, 'Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up', Clinical and Experimental Dermatology, vol. 41, no. 5, pp. 529-32. https://doi.org/10.1111/ced.12842

APA

Greenblatt, D. T., Benton, E. C., Groves, R. W., & Setterfield, J. F. (2016). Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up. Clinical and Experimental Dermatology, 41(5), 529-32. https://doi.org/10.1111/ced.12842

Vancouver

Greenblatt DT, Benton EC, Groves RW, Setterfield JF. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up. Clinical and Experimental Dermatology. 2016 Jul;41(5):529-32. https://doi.org/10.1111/ced.12842

Author

Greenblatt, D T ; Benton, E C ; Groves, R W ; Setterfield, J F. / Crescendo response to rituximab in oral pemphigus vulgaris : a case with 7-year follow-up. In: Clinical and Experimental Dermatology. 2016 ; Vol. 41, No. 5. pp. 529-32.

Bibtex Download

@article{417e316b30e54b90b77d435c8761d8d9,
title = "Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up",
abstract = "Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucous membranes. Rituximab, a CD20 chimeric monoclonal antibody, has efficacy in PV management. We report a case of severe oral PV that showed a progressive response to repeated courses of rituximab, culminating in a rapid response within 4 weeks following severe relapse 4 years after initial therapy. It demonstrates the progressively shorter time to achieve partial or complete remission following rituximab infusions, combined with minimal adjuvant therapy over a 7-year follow-up period.",
author = "Greenblatt, {D T} and Benton, {E C} and Groves, {R W} and Setterfield, {J F}",
note = "{\textcopyright} 2016 British Association of Dermatologists.",
year = "2016",
month = jul,
doi = "10.1111/ced.12842",
language = "English",
volume = "41",
pages = "529--32",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Crescendo response to rituximab in oral pemphigus vulgaris

T2 - a case with 7-year follow-up

AU - Greenblatt, D T

AU - Benton, E C

AU - Groves, R W

AU - Setterfield, J F

N1 - © 2016 British Association of Dermatologists.

PY - 2016/7

Y1 - 2016/7

N2 - Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucous membranes. Rituximab, a CD20 chimeric monoclonal antibody, has efficacy in PV management. We report a case of severe oral PV that showed a progressive response to repeated courses of rituximab, culminating in a rapid response within 4 weeks following severe relapse 4 years after initial therapy. It demonstrates the progressively shorter time to achieve partial or complete remission following rituximab infusions, combined with minimal adjuvant therapy over a 7-year follow-up period.

AB - Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucous membranes. Rituximab, a CD20 chimeric monoclonal antibody, has efficacy in PV management. We report a case of severe oral PV that showed a progressive response to repeated courses of rituximab, culminating in a rapid response within 4 weeks following severe relapse 4 years after initial therapy. It demonstrates the progressively shorter time to achieve partial or complete remission following rituximab infusions, combined with minimal adjuvant therapy over a 7-year follow-up period.

U2 - 10.1111/ced.12842

DO - 10.1111/ced.12842

M3 - Article

C2 - 27061201

VL - 41

SP - 529

EP - 532

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 5

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454